Proteostasis Therapeutics Inc. recently announced key leadership appointments.
James M. DeTore has been appointed the company’s new CFO; Dr. Geoffrey S. Gilmartin was chosen as the new chief developmental officer; Marija Zecevic, Ph.D. will become its VP of business development; and Eric B. Rabinowitz has been elected as the company’s newest member of its board of directors.
“We couldn’t be more pleased to welcome Jim, Geoffrey and Marija as we expand our leadership team,” President and CEO of Proteostasis Therapeutics Meenu Chhabra said. “Jim’s breadth and depth of experience with small and large-scale biotech and pharmaceutical companies will be invaluable as we put into place the financial and operational infrastructure necessary to advance our clinical program. Likewise, Geoffrey’s extensive experience leading clinical development for companies such as AstraZeneca and Vertex Pharmaceuticals will help shape our regulatory and commercial strategies moving forward. Marija’s track record in driving business development initiatives will further support the execution of value-generating strategic transactions from our DRT platform.”
Chhabra also stated that the company looks forward to continued growth this year and that the company will be announcing additional clinical updates in the near future. “The appointment of Mr. Rabinowitz to our board brings the critical knowledge and experience to help drive progress and strategic direction for the company," he said.
DeTore joins the company from bluebird bio, Inc., where he served as CFO from 2014 through 2016, while Dr. Gilmartin comes to Proteostasis from AstraZeneca, where he most recently served as senior medical lead for global medicines development.
Zecevic has collaborated with Proteostasis Therapeutics on multiple projects since July 2014. She was the founder and managing director at Zebra Ventures, a consulting firm based in Italy.
Rabinowitz is the VP of global corporate development of Perrigo Company PLC.
Alerts Sign-up